icovamenib

AssetAlso BMF-219

Covalently inhibits menin, promoting pancreatic beta cell proliferation and enhancing GLP-1 receptor expression and insulin content.

Stage: Human trials
Modality: Small molecule
Target: MEN1; 3
Indications: 0
Trials: 1
Developer

Indications

3

Type 1 diabetes
Human trials, doi.org, 20 Jun 2025
Type 2 diabetes
Human trials, doi.org, 20 Jun 2025
Muscle atrophy
Preclinical, doi.org, 20 Jun 2025

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets2
Competitors12
Signals4

Every asset’s record: target, stage, trials and the evidence behind it.